Discover 2,411 paid clinical trials in Rockville, Maryland. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 2,411
Active & Responsive
Natural History Study of Biomarkers in Pulmonary Arterial Hypertension
for
Pulmonary Disease, Pulmonary Hypertension
Location: Bethesda MD
Sponsor: National Institutes of Health Clinical Center (CC)
Sex: All
Age: 18 - 70+
Code: NCT01730092
Recruiting
Active & Responsive
Tirzepatide in MetALD
for
Metabolic Alcohol-associated Liver Disease,
Location: Bethesda MD
Sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Sex: All
Age: 21 - 70+
Code: NCT07046819
Phase2, Recruiting
Active & Responsive
Distinguishing Tics and Functional Tics Using Clinical Neurophysiological Techniques
for
Tics, Functional Tics
Location: Bethesda MD
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Sex: All
Age: 18 - 70+
Code: NCT07137442
Recruiting
Active & Responsive
Natural History of Trisomy 8-Associated Autoinflammatory Disease (TRIAD) and Related Disorders
for
Trisomy 8 Mosaicism,
Location: Bethesda MD
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Sex: All
Age: 0 - 70+
Code: NCT07683104
Recruiting
Active & Responsive
Accuracy of 18F-Fluorocholine PET/MR and NeuroEXPLORER PET/CT Imaging for Localization of Parathyroid Tumors
for
Primary Hyperparathyroidism, Parathyroid Cancer,
Location: Bethesda MD
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Sex: All
Age: 18 - 70+
Code: NCT07444723
Phase2, Phase3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Active & Responsive
Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib
for
Chronic Lymphocytic Leukemia (CLL),
Location: Bethesda MD
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Sex: All
Age: 18 - 70+
Code: NCT07428707
Early_phase1, Recruiting
Active & Responsive
Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)